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Abstract: The aim of this prospective study was to define the flow cytometric characteristics of simultaneously
investigated bone marrow and peripheral blood plasma cells antigens expression in 36 plasma cell leukemia
(PCL) patients. The immunophenotypic profile of plasma cells was determined with a panel of monoclonal
antibodies. The antigen expression intensity was calculated as relative fluorescence intensity (RFI). Bone
marrow plasma cells showed expression of particular antigens in the following proportion of cases: CD49d
100%, CD29 94%, CD54 93%, CD44 83%, CD56 60%, CD18 26%, CD11b 29%, CD11a 19%, CD117 27%,
CD71 30%, CD126 100% and CD19 0%, while the expression of those antigens on peripheral blood plasma
cells was present in the following percentage of patients: CD49d 100%, CD29 96%, CD54 93%, CD44 95%,
CD56 56%, CD18 50%, CD11b 53%, CD11a 29%, CD117 26%, CD71 28%, CD126 100% and CD19 0%. The
expression of CD54 was significantly higher than that of adhesion molecules belonging to the integrin b2
family: CD11a, CD18 and CD11b, on both bone marrow and peripheral blood cells (p < 0.01). Expression of
CD18, CD11a and CD11b was differential between two cell compartments: lower on bone marrow and higher
on peripheral blood cells. We found that plasma cells in the bone marrow of patients with plasma cell leu-
kaemia showed significantly greater granularity and size than those in the peripheral blood (p = 0.0001 and
p = 0.04, respectively). However, no differences in cell size or granularity were revealed between bone marrow
plasma cells from patients with PCL and multiple myeloma. In conclusion, impaired expression of adhesion
molecules such as CD11a/CD18 (LFA-1) or CD56 may explain hematogenic dissemination characterizing
PCL. The following pattern of adhesion molecule expression according to the proportion of plasma cells
expressing a given antigen in peripheral blood and bone marrow and arranged in diminishing order may be
established: CD49d > CD44 > CD54 > CD29 > CD56 > CD18 > CD11b > CD11a. Immuno-phenotyping
of plasma cells in PCL, as in multiple myeloma, might be useful in detecting minimal residual disease in cases
with aberrant antigen expression and for selecting therapeutic agents towards specific membrane targets.
(Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 168–182)
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Introduction
Recent studies on myeloma cell associated antigens:
CD45, CD44, CD56, CD117, CD126 and CD138
have revealed their multiple roles in the biology of
this tumor. Besides their immunophenotypic marker
function, these antigens contribute relevant process-
es for cell survival, participate in lytic bone lesion for-
mation, and mediate the action of novel anti-myelo-
ma drugs and resistance to treatment [1–12].
CD38 is a common marker for a variety of diffe-
rent cell populations e.g. T-cells, B-cells, NK-cells. But
it has been found that a high-density CD38 expression
(CD38++) on the cell surface is a characteristic fea-
ture of normal and malignant plasma cells [13].
CD138 (syndecan-1), a molecule belonging to the
heparan sulfate family, is a marker of normal and
malignant plasma cells [14]. Retaining lymphocyte
antigen (CD45) on some plasma cells is interesting
in terms of plasma cell differentiation. Expression of
CD45 seems to be important for myeloma cell sig-
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naling and proliferation processes [15, 16]. Adhesion
molecules participate in cell-to-cell interactions, cell
migration and homing. Integrins, present on the cell
surface, play the role of receptors for particular pro-
teins of the extracellular compartment. They are
a family of heterodimeric molecules that share a com-
mon b1 chain (CD29) together with one of six a1
chains (a1–a6) (CD49 a–f). VLA-4, an integrin con-
sisting of a4 and b1 chains, is a molecule that enables
cell binding to extracellular matrix through fibronec-
tin. Apart from VLA-4 contribution, the direct con-
tact of lymphoid malignant cells with bone marrow
stromal cells is mediated by such molecules as a trans-
membrane glycoprotein CD54 (Intercellular Adhe-
sion Molecule-1, ICAM-1), a multistructural and
multifunctional glycoprotein CD44 (Homing Cell
Adhesion Molecule, H-CAM), and CD11a/CD18
(Lymphocyte Function Associated Antigen, LFA-1).
LFA-1 is a ligand for ICAM-1. An intercellular con-
tact mediated through LFA-1-ICAM-1 molecules is
a requisite of malignant plasma cell proliferation.
Novel aspects of CD44 expression for myeloma are
associated with its prognostic and possibly therapeu-
tic significance [17, 18].
Plasma cell leukemia (PCL) is a rare malignant
plasma cell disorder accounting for 2–3% of all plas-
ma cell dyscrasias [19]. It may develop during the
course of multiple myeloma (MM) (secondary PCL)
or it may be diagnosed as a primary manifestation of
the disease. Due to its low incidence, most publica-
tions on PCL are based on single case reports. Little
is known about the immunophenotype of tumor cells
in primary PCL because very few reports have looked
at the evaluation of single antigens expression on bone
marrow or peripheral blood plasma cells [20–29].
The aim of this prospective study was a parallel
assessment of expression of adhesion molecules, re-
ceptor for interleukin-6 (CD126), receptor for stem
cell factor SCF (CD117), and receptor for transfer-
rin (CD71) on plasma cells of peripheral blood and
bone marrow in 36 patients with PCL. Moreover, ex-
pression of some of these antigens was compared with
their expression on myeloma plasma cells, based on
our previous, partly-published, studies in MM pa-
tients [30, 31].
Material and methods
Patients
The study included 36 PCL (23 primary, 13 secon-
dary) and 47 MM patients hospitalized in the De-
partment of Hematology of the Institute of Hema-
tology and Transfusion Medicine in Warsaw between
1995 and 2009.
The following parameters were estimated at diag-
nosis for each patient: age, sex, complete blood ex-
amination, percentage of plasma cells in bone mar-
row (at bone marrow collection for FACS analysis,
regular bone marrow smears were performed stained
with May–Grünwald–Giemsa method), monoclonal
protein isotype (using Beckman Paragon Immuno-
fixation Electrophoresis Kit), urine immunoglobulin/
/24 hours, serum concentrations of monoclonal pro-
tein, albumin, calcium, creatinine, LDH and b2-mi-
croglobulin (using Beckman ARRAY 360 autoana-
lyzer), complete X-ray skeletal survey, and stage of
disease according to Durie and Salmon and also the
International Staging System for multiple myeloma
[32]. PCL was diagnosed where there was an abso-
lute plasma cell count of at least 2.0 × 109/l or 20%
of the total white blood cell count in the peripheral
blood of patients with other typical symptoms of
clonal plasma cell malignancy.
Each patient’s informed consent was obtained
prior to bone marrow aspiration or biopsy.
Cell preparation and immunofluorescence
Immunophenotyping was performed simultaneously
on fresh bone marrow and peripheral blood samples.
The samples were incubated with monoclonal antibo-
dies against the analyzed antigens for a time recom-
mended by the manufacturers of these antibodies. Cells
were stained with triple labeling with mouse anti-hu-
man monoclonal antibodies conjugated to respective
fluorochromes. Cell surface antigens were assessed by
direct immunofluorescence using fluorescein isothiocya-
nate (FITC), phycoerythrin (PE), phycoerythrin-cyanide 5
(PE-Cy5) conjugated monoclonal antibodies against
antigens: CD138-FITC, CD138-PE (Serotec, UK),
CD38-PE-Cy5, CD45-FITC, CD45-PE-Cy5, CD56-PE,
CD29-FITC, CD18-FITC, CD71-FITC, CD19-FITC,
CD20-PE, CD10-PE, k/l/CD19 (Dako, Denmark),
CD49d-PE, CD11b-PE, CD117-PE, CD33-PE, CD58-
PE (Becton Dickinson, USA), CD54-PE, CD44-FITC,
CD11a-PE, and CD126-PE (Beckman Coulter, USA).
Positivity levels were determined according to a FITC-,
PE-, PE-Cy5-conjugated isotypic Ig control.
Flow cytometry analysis
The samples were analyzed using flow cytometer
CytoronAbsolute with ImmunoCount II software
(Ortho, Raritan, NJ, USA). Ten thousand cells were
analyzed at a time. The subjects of analysis were plas-
ma cells identified on the basis of strong CD38 ex-
pression, expression of CD138 and CD45low/– as well
as their typical light scatter distribution. Monoclona-
lity was confirmed by immunoglobulin light chain
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analysis. All investigated antigens expression was ana-
lyzed on CD38++/CD138+ cells. The percentage of posi-
tive events in plasma cell subset was calculated and com-
pared to the isotype control. The results were present-
ed as a percentage of cells with expression of investigat-
ed antigen. The threshold criterion value for antigen
positivity was more than 20% positive plasma cells.
The intensity of particular antigen expression was
measured by an indirect quantification method pre-
viously described and the values of this expression
intensity were calculated as Relative Fluorescence
Intensity (RFI) indices [3]. To determine CD45 ex-
pression intensity on plasma cells, we applied a meth-
od of referring RFIs on monoclonal plasma cells to
RFIs on lymphocytes, and a score of CD45 RFI va-
lues on myeloma cells to CD45 RFI values on lym-
phocytes was calculated in particular patients.
A method of calculating RFI score using antigen ex-
pression as a reference point was applied in flow cy-
tometry methodics [33]. Standardization of flow cy-
tometry was performed with Dako fluorospheres cal-
ibration and external controls using CEQUAL.
Statistical analysis
To estimate the statistical significance of differences
observed between mean values for different analy-
sed group pairs, the Wilcoxon and Student’s tests were
used with Statistica software. Differences were con-
sidered significant for p < 0.05.
Results
The data referring to the patients’ characteristics is
set out in Table 1. Cell size and granularity, as well as
CD45 expression intensity on peripheral blood and
bone marrow plasma cells, are presented in Tables 2
and 3, respectively.
The results of antigen expression analysis in par-
ticular PCL patients are presented in Table 4, while
their frequency is summarized in Table 5. The rela-
tive numbers of plasma cells with a given antigen ex-
pression and values of expression intensity indices
(RFI) of those antigens in peripheral blood and bone
marrow of PCL and MM patients are compared in
Tables 6 and 7, respectively.
Cell size and granularity
Two parameter cytograms based on forward scatter
height (FSC) and size scatter height (SSC) of plasma
cells were designed. SSC (side scatter channel) is
a rough indicator of cellular granularity and number
of organelles. The signal collected by the FSC detec-
tors is proportional to cell size [34].
Bone marrow plasma cells in PCL showed signifi-
cantly greater granularity and greater size than those
in peripheral blood (p = 0.001 and p = 0.04, respec-
tively) (Figure 1). This difference was found in al-
most all patients. However, no differences in cell size
or granularity were revealed between bone marrow
plasma cells in PCL and those in MM (Table 2).
Expression of particular antigens
CD45
CD45 RFI on plasma cells in relation to CD45 RFI
on lymphocytes in the same patients was analyzed.
Intensity of CD45 expression on peripheral blood and
bone marrow PCL plasma cells was low and uniform,
while the values of CD45 RFIs on lymphocytes were
high (Table 3). A score of RFI value on plasma cells/
/RFI value on lymphocytes for CD45 antigen was cal-
culated. The values of this score ranged from 0.0 to
0.8, with a mean of 0.2 ± 0.3. One may assume that
the values of the score exceeding this mean value in-
dicate CD45low cells, while those below this mean va-
lue correspond to CD45low/– cells.
Although most PCL cases presented with low and
relatively homogeneous CD45 expression intensity,
in particular cases we also observed such a conspicu-
ous diversity of this expression that two subsets of
plasma cells with different values of RFI (R2 and R3)
could be distinguished (Figure 2)
No differences in CD45 RFI of PCL plasma cells
between peripheral blood and bone marrow compart-
ment were found; similarly, no differences in CD45
RFI of bone marrow plasma cells between PCL and
MM patients were revealed (Table 3). This may indi-
cate a similar degree of maturity of plasma cells in bone
marrow and peripheral blood in both PCL and MM.
CD138 (Syndecan-1)
Expression of CD138 antigen was found on both bone
marrow and peripheral blood leukemic cells in all
patients (Tables 4, 5).The expression of this antigen
was very strong (Table 6). CD138 expression intensi-
ty (CD138 RFI) on bone marrow and peripheral
blood PCL plasma cells was similar in both individu-
al patients and the whole group of patients (Table 6).
Expression intensity of CD138 on myeloma bone mar-
row plasma cells showed heterogeneity from weak
(RFI = 4.7) to very high (RFI = 26.6); the mean
RFI value was 13.5 ± 4.3 (4.7–26.6), and the median
RFI value was 14.2 (Table 7). The proportion of CD38
positive myeloma plasma cells was very similar to that
of CD138.
In all patients, the expression of CD38 was also
revealed on leukemic cells of both cell compart-
ments.
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CD29/CD49d (VLA-4)
The molecule that showed the highest expression on
bone marrow and peripheral blood plasma cells of
all the analyzed adhesion molecules was CD49d
(a chain of VLA-4 molecule) (Tables 4–6). Positivity
of CD49d, as with CD29 positivity, was revealed in
all PCL patients. A statistically significant difference
in expression intensity of CD29 (CD29 RFI) was found
between peripheral blood and marrow compartments
(p = 0.009) (Table 6). Plasma cells from peripheral
blood presented with a higher expression, while those
of bone marrow presented with a lower one.
Table 1. Clinical and biological disease characteristics in plasma cell leukemia (PCL) and multiple myeloma (MM)
patients
Parameter Primary PCL Secondary PCL MM
n = 23 n = 13 n = 47
Gender
Female (%) 13 (57) 8 (62) 21 (45)
Male (%) 10 (43) 5 (38) 26 (55)
Age (years) mean ± SD; median 60.4 ± 14.2; 62.5 64 ± 11.4; 63 61.5 ± 9.4; 62
Bone marrow plasma cells (%) mean ± SD; median 70 ± 21; 80 75 ± 17; 75 45 ± 20; 40
Peripheral blood white blood cells × 109/L mean ± SD; median 26 ± 25; 15 9 ± 7; 6 4.0 ± 1.7; 4
Peripheral blood plasma cells (%) mean ± SD; median 41 ± 25; 31 24 ± 9; 26
Serum albumin < 3.5 [g/dL], % cases mean ± SD; median 33 25 20
3.7 ± 0.7; 3.9 3.4 ± 0.7; 3.6 3.5 ± 0.6; 3.7
Serum b2M > 5.5 [mg/L], % cases mean ± SD; median 80 40 21
10.8 ± 9.9; 8.4 5.6 ± 5.2; 2.9 4.8 ± 4.3; 4.4
Serum LDH > 450 [U/L], % cases mean ± SD; median 40 66 12
685 ± 1011; 389 1356 ± 1312; 720 370 ± 174; 328
Serum calcium > 2.75 [mmol/L], % cases 52 30 10
Serum creatinine > 2.0 [mg/L], % cases 33 23 17
Monoclonal protein isotype , % cases
IgG 73 46 66
IgGk 46 23 40
IgGl 27 23 26
IgA 0 46 22
IgAk 0 23 11
IgAl 0 23 11
IgEk 4 0 0
Bence Jones 19 8 12
Kappa 19 0 10
Lambda 0 8 2
Nonsecretory 4 0 0
Monoclonal proteinuria, % cases 52 46 41
Stage of disease, % cases
Acc. Durie Salmon
I 15
II 15 22 23
III 85 78 62
Acc. ISS
I 40
II 20 32
III 80 28
Osteolysis present, % cases 67 85 72
Median survival time (months) 9 (0.5–46) 1.5 (0.2–7.0) 43 (2–132)
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CD44 (H-CAM)
Expression of CD44 on peripheral blood and bone
marrow plasma cells in PCL was high and uniform
(Table 6). This contrasts with the expression of this
antigen in MM where heterogeneity of CD44+ expres-
sion in bone marrow was found, with the proportion
of CD44 positive cells ranging in individual patients
from very low to very high. The difference in the rate
of CD44+ cells in bone marrow between PCL and MM
was statistically significant (p = 0.0062) (Table 7).
Figure 1. Comparison of CD138+ plasma cells in PCL in peripheral blood and bone marrow: PCL plasma cells in
peripheral blood (I) show less granularity (SSC) and smaller size (FSC) than those in bone marrow (II)
Table 2. “Granularity” and size of peripheral blood and bone marrow PCL plasma cells and bone marrow MM plasma cells
Parameter PCL p PCL MM p
Peripheral blood Bone marrow Bone marrow
mean ± SD mean ± SD mean ± SD
median (min.–max.) median (min.–max.) median (min.–max.)
Granularity (SSC) 554 ± 191 0.00014 786 ± 253 833 ± 260 0.249
480 (287–1064) 738 (384–1369) 803 (436–1449)
Size (FSC) 1308 ± 186 0.041 1439 ± 266 1414 ± 240 0.659
1273 (1037–1784) 1349 (1085–2257) 1405 (926–2232)
“Granularity” — Side scatter (SSC); Size Forward scatter (FSC) — in cytometry linear scale
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CD54 (ICAM-1)
A strong expression of CD54 on PCL peripheral blood
and bone marrow plasma cells was found in 93% of
patients (Tables 4–6) (Figure 3).
In MM patients, the expression of CD54 on bone
marrow plasma cells was also found in 93% of pa-
tients. Expression of CD54 was high (Table 7). The
mean percentage of cells with CD54 expression was
73 ± 25% (13–98), median 82, while mean CD54RFI
was 15.8 ± 4.5 (8.7–25.1), median 15.7. The propor-
tions of CD54+ cells and CD54 antigen intensity (RFI)
were positively correlated (r= +0.58565; p = 0.001).
This means that a plasma cell subset with a high pro-
portion of CD54+ cells is characterized by high CD54
expression intensity on particular cells.
CD11a/CD18 (LFA-1)
Most PCL patients did not display expression of
CD11a/CD18 (LFA-1) molecule on leukemic cells
(Figure 3). The proportion of CD18+ plasma cells
was higher in the peripheral blood than in bone mar-
row and the difference in the proportion of CD18+
plasma cells between those two compartments was
statistically significant (p = 0.0014). CD18 expression
intensity presented by CD18 RFI values behaved simi-
larly (p = 0.0021).This phenomenon may be associated
with distinct adhesive properties of these cells (Table 6).
Similarly, positivity of CD18 on plasma cells in pe-
ripheral blood was found in a higher proportion of pa-
tients than that in bone marrow (50% vs. 26%) (Table 5).
In PCL patients, a mean proportion of CD11a+
cells was higher in the peripheral blood than in bone
marrow (25.2 ± 26.7% vs. 13.3 ± 17.9, respectively;
p = 0.073) (Table 6). Similarly, slightly more PCL
patients showed CD11a positive plasma cells in pe-
ripheral blood than in bone marrow (29% vs. 19%).
Expression intensity (RFI) of CD11a was higher on
plasma cells of peripheral blood and lower on those
of bone marrow, and the difference was statistically
significant (p = 0.003) (Tables 5, 6).
CD11b
CD11b expression was differential depending on wheth-
er the leukemic cells belonged to the bone marrow or
the peripheral blood compartment. In PCL patients,
the mean proportion of CD11b+ cells in the bone mar-
Figure 2. Differential CD45 expression intensity on peripheral blood CD138+ plasma cells in PCL patient:
R2-CD45lowplasma cells, R3-CD45low/negative plasma cells
Table 3. CD45 expression intensity (RFI) on peripheral blood and bone marrow PCL plasma cells and bone marrow
MM plasma cells
Parameter PCL p PCL MM p
Peripheral blood Bone marrow Bone marrow
CD45low cells CD45low cells CD45low cells
mean ± SD mean ± SD mean ± SD
median (min.–max.) median (min.–max.) median (min.–max.)
RFI 5.0 ± 6.3 0.1716 3.1 ± 3.6 3.3 ± 2.3 0.731
2.3 (0.1–22.3) 1.8 (0.4–16.5) 2.7 (0.3–12.0)
Score RFI* 0.2 ± 0.3 0.446 0.2 ± 0.2 0.17 ± 0.11
0.1 (0.001–0.8) 0.1 (0.02–0.8) 1.5 (0.04–0.59) 0.1176
*Score RFI = RFI CD45low plasma cells/RFI CD45 lymphocytes
174 M Kraj et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0024
www.fhc.viamedica.pl
Table 4. Immunophenotype of bone marrow and peripheral blood plasma cells in particular patients with primary
(cases 1–23) and secondary (cases 24–36) PCL
1. BM – + 46% + + – 0 + + + – – – 0 0 – 0 0 0
PB – + 25% + + – 0 + + + + + – 0 0 – 0 0 0
2. BM – + 74% + + + + + + + + + + 0 0 + 0 – 0
PB – + 11% + + + + + + + + + + 0 0 + 0 – 0
3. BM – 0 22% + + – + + + + + + + 0 0 – 0 0 0
PB – 0 12% + + – + + + + + + + 0 0 + 0 0 0
4. BM – 0 41% + + – + + + + + – 0 0 – 0 0 0
PB – 0 22% + + – + + + + + + + 0 0 – 0 0 0
5. BM – 0 38% + + – + + + + – – + 0 0 – 0 0 0
PB – 0 22% + + – + + + + – – + 0 0 – 0 0 0
6. BM – + 74% + + – + + + + – – – 0 – + 0 0 0
PB – – 55% + + – + + + + – – – 0 – + 0 0 –
7. BM – – 57% + + + 0 0 0 + – – – 0 – – 0 – 0
PB – – 5% + + + 0 0 0 + – – – – – – 0 – 0
8. BM 0 0 27% + + + 0 0 0 – 0 0 + + 0 0 0 0 0
PB 0 0 9% + + + 0 0 0 + 0 0 0 – 0 0 0 0 0
9. BM – + 59% + + – + 0 0 + – – – + + – 0 0 –
PB – + 59% + + – + 0 0 + – – – – + – 0 – –
10. BM 0 0 37% + + + 0 0 0 + + – – – – – 0 0 0
PB 0 0 19% + + + 0 0 0 + + – – – – – 0 0 0
11. BM 0 0 42% + + – 0 0 0 + – – 0 + – 0 + 0 0
PB – 0 32% + + – + + + + – – 0 + – 0 + – –
12. BM – – 59% + + + + 0 0 + – – 0 0 – – – 0 –
PB – 0 25% + + + + 0 0 + – – 0 0 – – 0 0 –
13. BM 0 64% + + + 0 0 0 + 0 – – + + – 0 0 0
PB – 0 62% + + + 0 0 0 + 0 – – + + 0 0 0 0
14. BM + 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
PB – 0 56% + + – + + + + 0 – 0 0 – 0 0 – –
15. BM – 0 58% + + – + + + + 0 – 0 0 + 0 + – –
PB – 0 79% + + – + + + + 0 – 0 0 – 0 + – –
16. BM – 0 45% + + – + + + + + + – 0 0 – + 0 0
PB – 0 25% + + – + + + + + – – 0 0 – + 0 0
17. BM – 0 61% – + + + – – – 0 – 0 + 0 –
PB 0 0 41 + + – 0 + + + – – 0 0 0 + 0 0
18. BM – – 54% + + + – + + + – – 0 – + 0 + 0 0
PB – 0 31% + + + + + + + – – 0 0 + 0 + 0 0
19. BM – 0 42% + + + 0 0 0 0 0 – 0 0 0 0 0 0 0
PB – 0 47% + + + + + + + – – 0 0 – 0 + 0 0
20. PB – – + 0 0 0 0 0 – – – 0 0 – 0 – 0
21. PB – 0 + + 0 0 0 0 0 0 0 0 0 + 0 0 0 –
22. BM – 0 + 0 0 0 0 0 0 0 0 0 – 0 0 0 0
23. BM –+ 0 + + + + 0 0 + 0 0 0 0 – 0 0 0 0
24. BM – 0 54% + + + + + + + – – – 0 0 + 0 0 0
PB – 0 10% + + + + + + + + + + 0 + – 0 0 +
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row was less than half that in the peripheral blood (15.9 ±
± 23.7 vs. 32.7 ± 25.8, respectively; p = 0.0725) (Table 6).
Similarly, fewer patients showed positivity of CD11b on
plasma cells in the bone marrow than in the peripheral
blood (29% vs. 53%) (Table 5).
CD56 (NCAM)
Expression of CD56 in PCL patients did not produce
a uniform pattern. Nine of 12 (75%) patients with
PCL in terminal stage of MM showed CD56 expres-
sion on bone marrow plasma cells at MM diagnosis,
and on both bone marrow and peripheral blood plas-
ma cells in the leukemic phase of disease. In the re-
maining three (27%) cases, CD56 expression was
found neither at the time of MM diagnosis nor in the
leukemic phase of the disease.
Only nine of 20 (45%) patients with primary PCL
displayed CD56 expression on both bone marrow and
peripheral blood plasma cells. A less frequent CD56
positivity was found in primary PCL (45% of cases) as
Table 4. Continued
25. BM 0 0 88% + + + – + + – – – 0 0 – 0 0 0 0
PB 0 0 27% + + + – + + – – – 0 0 – 0 0 0 0
26. BM – 0 88% + + + – + + + – – – 0 0 + 0 0 0
PB – 0 23% + + + + + + + + + + 0 0 + 0 0 0
27. BM 0 0 31% + + – 0 + 0 + + + 0 0 – + 0 0 0
PB 0 0 8% + + – 0 + 0 + + + 0 0 – + 0 0 0
28. BM – 0 40% + + + + + + + – – – 0 0 + 0 – 0
PB – 0 4% + + + + + + + + + + 0 0 – 0 – 0
29. BM – 0 38 + + + 0 – 0 + – – 0 0 + – 0 0 0
PB – 0 7% + + + 0 – 0 + + – 0 0 – – 0 0 0
30. BM – 0 + + – + + + + – 0 + – – 0 0 0
PB – 0 + + – 0 + + + + 0 + 0 – – 0 0 0
31. BM – 0 66% + + + 0 0 0 – – – 0 – – – 0 0 0
PB – 0 18% + + + 0 0 0 – – – 0 – – – 0 0 0
32. BM – 0 80% + + + + + + + 0 – 0 0 – 0 + – 0
PB – 0 42% + + + + + + + 0 – 0 0 – 0 + – 0
33. BM – 0 15% + + + 0 0 0 0 0 0 + 0 0 – 0 0 0
PB – 0 6% + + + + + + + + + + 0 0 – 0 – –
34. PB – 0 36% + + – + + + + 0 – 0 0 ± 0 + 0 –
35. PB – 0 42% – + + 0 0 + + 0 – 0 0 – 0 + 0 0
36. BM – 0 47% + + + 0 + + + – – 0 0 0 0 + 0 0
PB – 0 23% + + + 0 + + + – – 0 0 0 0 + 0 0
BMI — bone marrow plasma cells; PB — peripheral blood plasma cells; “+” — expressed; “–“ — not expressed; 0 — not determined
Figure 3. Differential expression of adhesion molecules on peripheral blood CD138+ plasma cells in PCL: high
proportion of CD54+cells and low proportion of CD11a+ cells
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Table 5. Frequencies of analyzed antigens expression on bone marrow and peripheral blood plasma cells in patients
with  PCL
Antigen CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD
19 20 38 138 56 44 29 49d 54 18 11a 11b 58 117 71 126 10 33
Bone marrow
Number of pa- 26 5 32 32 30 18 17 17 28 23 27 17 6 18 20 7 5 4
tients analyzed
Number of 0 4 32 32 18 15 16 17 26 6 5 5 4 5 6 7 0 0
positive (+1)*
Percentage 0 80 100 100 60 83 94 100 93 26 19 29 66 27 30 100 0 0
positive
Peripheral
blood
Number of 28 6 34 34 32 20 24 23 32 26 31 17 7 21 20 10 10 10
patients
analyzed
Number of 0  3 33 34 18 19 23 23 30 13 9 9 2 6 5 10 0 1
positive
Percentage 0 50 97 100 56 95 96 100 93 50 29 53 28 28 25 100 0 10
positive
*In 1 patient 2 plasma cell populations CD19– and CD19+ present
Table 6. Relative numbers and relative fluorescence intensity (RFI) of bone marrow and peripheral blood plasma cell
adhesion molecules subpopulations in PCL patients
Subpopulation Percentage of  subset cells p Relative fluorescence intensity p
Bone marrow Peripheral Bone marrow Peripheral
mean ± SD blood mean ± SD blood
median mean ± SD median mean ± SD
(min.–max.) median (min.–max.) median
(min.–max.) (min.–max.)
Plasma cells 50.3 ± 18.5 28.4 ± 20.2 0.0001
% WBC 45 (16–86) 23 (4–79)
CD49d 81.4 ± 23.6 85.9 ± 18.9 0.5976 12.9 ± 4.4 14.6 ± 3.3 0.4036
88 (25–100) 93.5 (38 –100) 11.5(7.7–18.3) 13.1 (10.8–21.1)
CD29 62.5 ± 28.8 69.5 ± 31.1 0.5168 7.9 ± 0.9 10.0 ± 2.4 0.0009
64 (1–94) 77 (11–99) 7.7 (6.9–9.6) 9.9 (5.5–15.3)
CD44 78.8 ± 33.1 83.7 ± 23.3 0.6470 13.6 ± 2.7 15.5 ± 4.8 0.2956
97 (5–99) 97 (27–100) 13.4 (8.2–17.7) 13.9 (12.3–29.2)
CD56 43.7 ± 40.3 40.4 ± 36.6 0.7568 16.5 ± 4.6 14.9 ± 3.3 0.1728
50.5 (1–99) 23 (1–99) 15.6 (10.0–25.6) 15.8 (9.5–20.6)
CD54 70.9 ± 31.1 72 ± 30.2 0.8962 16.2 ± 4.2 15.6 ± 3.2 0.6178
87 (4–99) 84 (1–99) 16.3 (8.9–25) 14.7 (9.9–21.1)
CD18 16.3 ± 16.0 36.7 ± 20.5 0.0014 12.8 ± 3.4 16.2 ± 1.5 0.0021
11 (1–75) 38.5 (1–82) 14.1 (4.1–16.4) 16.6 (13.7–19.0)
CD11a 13.3 ± 17.9 25.2 ± 26.7 0.073 14.4 ± 3.0 18.7 ± 3.7 0.003
6.5 (1–90) 16 (1–86) 14.7 (9.7–18.5) 19.9 (11.1–22.3)
CD11b 15.9 ± 23.7 32.7 ± 25.8 0.0725 17.3 ± 4.3 20.3 ± 3.0 0.0681
7.5 (1–96) 31 (1–88) 16.8 (10.8–23.1) 19.9 (15.1–25.1)
CD138 53.4 ± 18.0 30.9 ± 22.3 0.002 16.9 ± 4.4 17.6 ± 4.1 0.5537
54 (25–86) 26 (4–79) 18.2 (7.5–22.2) 18.7 (11.3–23.5)
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compared to PCL developed in the end phase of MM
(75% of cases) (p = 0.04).
CD126 (IL-6R)
All ten analyzed patients with PCL showed expression of
CD126 on plasma cells in both peripheral blood (mean:
61% ± 27%, median 53%, range 32–98%) and bone
marrow (mean: 58% ± 23%, median 56%) (Figure 4).
CD117 (c-kit)
In seven out of 23 (30%) evaluated PCL patients,
plasma cells showed CD117 expression, whereas in
the other 16 (70%) patients they did not. CD117 an-
tigen positivity was found in five patients with prima-
ry PCL and in two patients with PCL which deve-
loped in the end phase of multiple myeloma. In
CD117-positive PCL cases, expression of CD117 was
detected in bone marrow plasma cells as well as in
peripheral blood plasma cells. In only one case, the
bone marrow plasma cells expressed CD117, while
those of peripheral blood did not.
CD71 (Tr1R)
The proportion of cells with expression of CD71 in
the population of plasma cells in peripheral blood
was low (mean value of CD71+ cells was 16.5 ± 16.4,
median 13.5, range 1–67). The figures representing
proportions of CD71+ cells of one quarter of patients
were above the threshold value (20% and more). No
differences in either proportion of CD71-positive cells
or expression intensity of this antigen between pe-
ripheral blood and bone marrow compartments were
found (p = 0.713 and p = 0.831, respectively). The
proportion of CD71+ cells in the bone marrow of MM
patients was significantly higher than that of PCL
patients (p = 0.013) (Table 7) while expression in-
Figure 4. High expression of interleukin-6 receptor (CD126) on CD138+ plasma cells in peripheral blood (A) and bone
marrow (B) in PCL
Table 7. Comparison of relative numbers of bone marrow plasma cell CD138, CD44, CD54, CD56, CD71 subpopula-
tions in PCL and MM patients
Subpopulation Percentage of subset cells p
PCL patients MM patients
mean ± SD mean ± SD
median (min.–max.) median (min.–max.)
CD138 53 ± 18 21 ± 17 0.00001
54 (25–86) 13 (4–68)
CD44 79 ± 33 46 ± 36 0.0062
97 (5–99) 45 (1–99)
CD54 71 ± 31 73 ± 25 0.6207
87 (4–99) 82 (13–98)
CD56 44 ± 40 67 ± 37 0.01
50 (1–99) 75 (1–99)
CD71 22 ± 22 34 ± 26 0.0133
14 (1–68) 29 (2–81)
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tensity of CD71 on plasma cells of the bone marrow
compartment was similar between those entities
(mean: 9.0 ± 3.9, median: 7.7, range 3.6–17.6).
CD19
Expression of CD19 was found in none of the ana-
lyzed cases, but in one case of a patient with an un-
usual rarely occurring monoclonal protein of IgEk
class, two populations of cells were revealed in the
bone marrow: large, granular cells displaying plasma
cell features with CD38++, CD138+, CD56+, CD45–,
CD19– immunophenotype constituted approximate-
ly 30% of all nucleated cells, while 11% of cells were
lymphoplasmocytes with CD19+dim, CD38++, CD138+
immunophenotype.
Results recapitulation
Overall, the expression of analyzed antigens on leu-
kemic cells did not differ significantly between pa-
tients with primary PCL plasma cells and those with
plasma cell leukemia terminating advanced MM. As
previously mentioned, there were slight differences
concerning CD56 antigen.
On the basis of our analysis of particular surface
antigens expression on leukemic cells, it was possible to
establish the immunophenotype of PCL cell as follows:
CD19–, CD45–, CD38++, CD138+, CD54+,CD49d+,
CD29+, CD44+, CD126+. Expression of CD18, CD11a,
and CD11b differed in two cell compartments: lower in
the bone marrow and higher in the peripheral blood
cells. In most patients, PCL cells did not display ex-
pression of CD56, CD71 and CD117 in both cell com-
partments.
With regard to the expression of adhesion mole-
cules (‘adhesion immunophenotype’ of plasma cells
in PCL), presented as a proportion of plasma cells
with expression of a given molecule, one may arrange
the following sequence of antigen expression on pe-
ripheral blood and bone marrow cells (in diminish-
ing order): CD49d > CD44 > CD54 > CD29 >
> CD56 > CD18 > CD11b > CD11a.
The expression of CD54 was significantly higher
than that of adhesion molecules from integrins b2
family. The levels of statistical significance (p) of this
difference in relation to particular molecules were as
follows: for CD11a in comparison between periphe-
ral blood compartments (p = 0.01) and inter-bone
marrow compartments (p = 0.000006); for CD18 in
peripheral blood compartments (p = 0.01), and in
bone marrow compartments (p = 0.00007); and for
CD11b in comparison between peripheral blood com-
partments (p = 0.02) and in bone marrow compart-
ments (p = 0.0001).
Discussion
Immunophenotypic analysis of leukemic cells showed
a strong expression of CD38, and common presence
of CD138 expression, in all PCL patients.
It is generally accepted that a strong CD38 ex-
pression is characteristic of myelomatous plasma cells.
Our study unequivocally demonstrated the presence
of CD38 expression on leukemic PCL cells, not only
in the bone marrow but also in the peripheral blood,
thus on those cells that had lost their communication
with the bone marrow environment.
The presence of CD38 expression on myeloma
cells beyond the bone marrow i.e. in peripheral blood
or body fluids, has been reported [21, 23, 35, 36].
Our study revealed expression of CD138 on PCL
leukemic cells. The CD138 antigen is nowadays con-
sidered as one of the most specific markers of mono-
clonal plasma cells. Our findings may be important,
especially when taken together with the observation
of Jourdan et al. [37] that expression of CD138 is limi-
ted exclusively to living, and not apoptotic, myeloma
cells. It may importantly impact on the purging of
malignant plasma cells from autologous stem cell
grafts. A recently-reported regulatory function of
CD138 in myeloma proliferation, resulting from in-
volvement of syndecan-1 in both the angiogenesis and
apoptosis processes, may explain the relationship
between surface cell expression of this molecule and
stimulation of plasma cell proliferation [37, 38].
CD138 plays a role of co-receptor for numerous mye-
loma cells growth factors such as BAFF/APRIL, EGF,
and HGF [39, 40]. The demonstration of CD138 ex-
pression on PCL leukemic cells in our study aligns
with the results of another analysis [23].
We also found that leukemic cells from bone mar-
row and peripheral blood compartments do not ex-
press LFA-1 in most PCL patients, while the expres-
sion of ICAM-1, a ligand for LFA-1, is very strong.
A disclosed expression pattern (high ICAM-1 and
very low LFA-1 expression) on bone marrow cells in
PCL resembles a common expression profile presen-
ted by bone marrow myeloma plasma cells. Howev-
er, we should stress that expression of both ligands
on leukemic PCL cells may be affected by the envi-
ronment in which they reside. Thus, it has been shown
that leukemic cells forming a cutaneous tumor show
an immunophenotype CD11a+/CD18+ and CD54–
(LFA1+ and ICAM-1–) that is the opposite to the one
aforementioned [41]. This finding underscores once
again the pivotal role of that ligand pair for migra-
tion and homing of tumor cells. A very significant
decrease of LFA-1 expression found in both PCL cell
compartments may be of particular importance for
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PCL pathogenesis. Deficiency of LFA-1 molecule is
believed to be a poor prognostic factor in monoclonal
gammopathies, and other lymphoproliferative disor-
ders, because it facilitates the escape of cells from
immunological surveillance [42, 43]. A lack of expres-
sion of another integrin belonging to the LFA family,
namely LFA-3 (CD58), on leukemic cells in PCL has
also been reported [44]. In most patients in our study,
peripheral blood and bone marrow leukemic cells did
not display CD58 expression.
Most PCL patients in our study explicitly expressed
another integrin molecule, VLA-4, on bone marrow
and peripheral blood cells. Opinions on the role of
late activation antigens in PCL are divided. Some
authors have observed the expression of all these
molecules on leukemic cells, while others have found
the presence of VLA-4 combined with an absence of
VLA-5 expression and stated that this surface antigen
constellation was important for leukemic proliferation
[45, 46]. The expression of VLA-4 on the leukemic
cells is a requisite of their increased invasiveness be-
cause contact between this antigen and its ligand in
a capillar wall leads into extravasation of those cells
from the blood into extravascular space [47].
A similar role may be played by the third of the
analyzed integrin molecules — CD11b. The charac-
teristic pattern of CD11b expression observed in our
study i.e. decreased bone marrow expression and in-
creased expression on circulating cells, suggests a sub-
stantial role for this molecule in the leukemic pro-
cess.
Acquisition of CD11b expression by peripheral
blood leukemic cells facilitates egress of those cells
through the capillar wall and leads to the expansion
of proliferation which is so characteristic of the leu-
kemic process [48]. It is also believed that among
CD11b+ cells, there may be a subset of cells which
survive chemotherapy and are responsible for a post-
-treatment relapse of plasma cell proliferations [49].
Therefore, removal of these cells from the periphe-
ral blood, by means of targeted immunotherapy or
application of cell chemosensitivity methods, may be
of relevant therapeutic importance [49].
The expression of H-CAM on leukemic cells ana-
lyzed in our study was high. H-CAM is a very impor-
tant molecule for lympho- and plasma cell prolifera-
tions and its expression shows differential effects on
plasma cell tumors [50, 51].This glycoprotein is in-
volved both in inter-cellular interactions of tumor cells
with other bone marrow cells and interactions of tu-
mor cells with bone marrow extracellular matrix via
its linkage with hyaluronic acid. CD44 plays a crucial
role in the adherence of blood monoclonal cells into
fibroblasts and belongs to those adhesion molecules
whose direct contact with stromal receptors leads into
a release of numerous cytokines [50, 52]. In some lym-
phoproliferative disorders, increased H-CAM expres-
sion has been found, especially in cases of extrame-
dullar tumor expansion [53]. H-CAM may also have
a regulatory effect on LFA-3 and CD2 interactions,
thus on the relationship between plasma cells and T
lymphocytes [44].
In our study, the object of analysis was the so-called
‘standard CD44’ without determining the expression
of particular isoforms of this molecule. Expression of
some of those isoforms, especially v6, v7, v8, and v10,
unfavorably correlates with certain clinical determi-
nants of plasma cell tumors, including duration of
patients’ survival time [54, 55].
An important finding of this analysis is the dem-
onstration of differential expression of CD56 in PCL
patients. In most patients with primary PCL, the bone
marrow and peripheral blood plasma cells did not
show CD56 expression, although in approximately
45% of patients, expression of this antigen was found.
The CD56 antigen, identical with a 140 kD isoform
of adhesion molecule N-CAM, shows an ability both
to homotypic binding in intercellular interactions and
to heterotypic binding with heparane sulfate — an
extracellular matrix proteoglican [52]. The N-CAM
is an example of a ‘foreign’ antigen for plasma cells
with respect to lymphoid cell ontogenesis. Its acqui-
sition, according to the first reports on this antigen
expression in MM, imprints a ‘mark of malignancy’
on plasma cells [13, 56, 57]. However, some authors
have questioned whether CD56 expression is exclu-
sively limited to myeloma plasma cells [58].
On the other hand, a lack of CD56 expression is
considered to be an immunophenotypic marker of
leukemic cells in PCL. In addition, the appearance of
a decreased CD56 expression on bone marrow plasma
cells is considered an unfavorable factor and a hallmark
of leukemic transformation of MM. Generally, the ab-
sence of N-CAM expression is attributed to a less ma-
ture plasma cell immunophenotype [43, 58–60].
As mentioned above, in our study, in 55% of pri-
mary PCL cases malignant plasma cells did not ex-
press CD56, while the incidence of CD56 positivity in
secondary PCL did not differ from that observed in MM
cases. Lack of CD56 expression on malignant plasma
cells in 81% of patients with primary PCL or secondary
PCL has been reported [22]. The effect of CD56 ab-
sence on malignant plasma cells on PCL development
may result both from weaker myeloma cell-to-cell and
myeloma cell-to-bone cell interactions in CD56–/weak MM
and increased secretion of MMP-9 by CD56– cells lea-
ding to degradation of basal membrane and extramed-
ullary spreading of malignant cells [22, 34].
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The demonstration of CD56 expression hetero-
geneity in PCL patients in our study contrasts with
opinions previously published. However, in one study
performed on a larger group of PCL patients, the
authors paid attention to a differential CD56 expres-
sion on leukemic cells [61]. Moreover, our previous
study found that CD56 expression carries no distinct
adverse prognosis and that lack of CD56 expression
does not define a unique clinicopathological or prog-
nostic entity in multiple myeloma [4].
In all analyzed PCL cases, a strong expression of
IL-6 receptor (CD126) was found. IL-6 is widely ac-
cepted as the most relevant growth factor for myelo-
ma cells in vitro and in vivo [15, 62, 63]. IL-6 affects
the survival and proliferation of myeloma cells via
autocrine and/or paracrine mechanisms. Our obser-
vation may explain the aggression of plasma cell pro-
liferation in PCL and suggests that the application of
IL-6 antibody in combination with IL-6 R antibody
in PCL therapy could be more effective than IL-6
antibody alone [8, 12].
More than a quarter of our PCL patients’ plasma
cells displayed CD117 expression. C-kit (CD117),
a product of c-kit protooncogene, is a 145 kD trans-
membrane protein with activity of class III receptor
tyrosine kinase. Recent studies have found c-kit anti-
gen to be a ‘tumor associated marker’. Together with
CD38 and CD138, it may be of value in identifying
the malignant clone in minimal residual disease [3].
It may also prompt a consideration of the usefulness
of therapy with tyrosine kinase inhibitors in the mana-
gement of c-kit positive plasma cell proliferations
[2, 5]. Mateo et al. suggested that the expression of
CD117 is associated with more favorable outcomes
[34, 64]. However, we did not observe this in our
present or previous studies [3].
In a quarter of our PCL patients, plasma cells
showed CD71 expression. Proliferating neoplastic
cells require an adequate supply of iron. Thus the
expression of transferrin receptor 1 (CD71), one of
the ‘classical’ markers upregulated upon B-cell acti-
vation, is important. Ng et al. [65] have reported that
an anti-human tranferrin receptor IgG3–avidin fu-
sion protein inhibits the proliferation of human ma-
lignant B cells and plasma cells (by inducing lethal
iron deprivation) and suggested that the molecule
may be useful in the treatment of B-cell malignan-
cies such as MM and PCL.
Lack of B-cell marker- CD19– expression was ob-
served in all our PCL patients. We must emphasize
that in one case of PCL with IgEk monoclonal pro-
tein in a patient’s bone marrow, apart from a popula-
tion of large granular CD38++, CD138+, CD56+,
CD45–, CD19– cells corresponding immunophenotyp-
ically to plasma cells, there was also present a less
numerous CD19+dim, CD38++, CD138+cell subset
with lymphoplasmocyte features.
In the study by Bataille et al. [34], CD19 was found
in 2.5% (nine out of 362) myeloma cases. Lack of
CD19 constitutes a marker of plasma cell malignan-
cy. The role of the absence of CD19 expression, if
any, has yet to be elucidated.
The expression of a second lymphocyte marker,
CD20, was assessed in seven cases of PCL only; in
three cases, its presence was found. In the study by
Robillard et al. [66], CD20 was found in 14% (29 out
of 209) of myeloma cases at diagnosis.
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